Intrauterine prp slow release device

Abstract

The application discloses an intrauterine PRP slow-release device, which comprises a balloon, a flow guide mechanism arranged at the lower end of the balloon and used for injecting liquid into the balloon, and a connecting pipe, a partition plate, a first flow channel, a first elbow pipe, a first catheter seat and a first filling valve. The connecting pipe is fixedly arranged at the lower end of the balloon, and the partition plate is fixedly arranged at the middle of the inner side of the connecting pipe. The application is innovative in the treatment means of intrauterine PRP injection. A part of PRP liquid is temporarily reserved in the flow channel connected with the balloon, so that the amount of PRP liquid injected into the uterine cavity at one time can be reduced, and the pain of the patient can be relieved. Subsequently, the remaining PRP liquid can be automatically and gradually released in the uterine cavity according to the uterine cavity activity of the patient in the subsequent life of the patient, so that the frequency of the patient going to the hospital can be reduced, and the continuously released PRP liquid can continuously treat the inside of the uterine cavity of the patient, and help the repair and proliferation of the endometrium.

Description

Technical Field

[0001] This invention relates to the field of PRP sustained-release therapy technology, specifically to an intrauterine PRP sustained-release device. Background Technology

[0002] In the current reproductive-age population, intrauterine adhesions seriously affect patients' fertility and pregnancy success rate. Intrauterine adhesions often occur secondary to intrauterine traumatic surgery, tuberculosis infection, etc., and are also a common complication after induced abortion. For the treatment of intrauterine adhesions, hysteroscopic adhesiolysis is still the gold standard. After intrauterine adhesion separation, it is now clear that intrauterine stents are needed to help patients prevent re-adhesion and promote endometrial growth.

[0003] Patients who have undergone intrauterine adhesion lysis or have thin endometrium are prone to recurrent implantation failure, placing significant pressure on patients and society. Currently, intrauterine PRP infusion is increasingly being promoted as a treatment for patients with thin endometrium after intrauterine adhesion lysis. Intrauterine PRP infusion refers to the infusion of the patient's own concentrated platelet-rich plasma (PRP) into the uterine cavity. PRP is a platelet concentrate extracted from fresh whole blood after centrifugation, which is then mixed with other drugs. Its platelet content is much higher than that of ordinary plasma, and it contains a large number of various growth factors, cytokines, chemokines, proteins, peptides, and other substances, which can promote endometrial growth and embryo implantation.

[0004] In existing intrauterine PRP treatment techniques, PRP liquid (platelet-rich plasma) is generally prepared into 5-10ml / bags. The normal volume of the uterine cavity is 5ml. Currently, the infusion begins on the first day after menstruation ends, once every other day, for 3-5 infusions. Since the infusion is done every other day, the actual duration is 6-10 days.

[0005] The existing procedures for intrauterine PRP treatment have the following drawbacks.

[0006] 1. Each time PRP solution is injected, it is placed into the uterine cavity using a syringe and catheter. The uterine cavity is rapidly filled with the injected PRP solution without any slow-release function. As a result, the patient will experience significant pain and discomfort during this procedure.

[0007] 2. Because PRP treatment has a long treatment cycle, patients need to come to the hospital every other day for repeated infusion, which makes the whole treatment cycle quite troublesome. In addition, the balloon needs to be removed and the PRP liquid injection tube needs to be inserted each time during infusion, making the whole process quite troublesome.

[0008] Therefore, an intrauterine PRP sustained-release device is needed to address the above problems. Summary of the Invention

[0009] The purpose of this invention is to provide an intrauterine PRP sustained-release device to solve the problems mentioned in the background art.

[0010] To achieve the above objectives, the present invention provides the following technical solution: an intrauterine PRP sustained-release device, comprising a balloon, wherein a flow guiding mechanism for injecting fluid into the balloon is provided at the lower end of the balloon, the flow guiding mechanism comprising a connecting tube, a diaphragm, a first flow channel, a first bend, a first catheter seat, and a first filling valve, wherein a connecting tube is fixedly provided at the lower end of the balloon, a diaphragm is fixedly provided in the middle of the inner side of the connecting tube, a first flow channel is provided inside the connecting tube at the lower end of the diaphragm, a first bend is fixedly provided on one side of the first flow channel, a first filling valve is fixedly provided at the lower end of the first bend, and a sustained-release treatment mechanism for intrauterine PRP injection treatment is provided inside the connecting tube.

[0011] Preferably, the sustained-release treatment mechanism includes a second flow channel, a second bend, a second catheter seat, and a second filling valve. The connecting tube has a second flow channel at the upper end of the partition. A second bend is provided on one side of the surface of the second flow channel. A second catheter seat is fixedly provided at one end of the second bend. A second filling valve is fixedly provided on one side of the surface of the second catheter seat. The sustained-release treatment mechanism allows for convenient injection of PRP liquid into the second flow channel using a syringe. The PRP liquid will then fill the second flow channel. Continued injection of PRP liquid using the syringe will cause a portion of the PRP liquid to be squeezed out from the sealing valve and enter the uterine cavity for treatment through the outlet. The remaining PRP liquid in the second flow channel is retained for slow release later. It should be noted that the first and second filling valves in this application are existing technologies and only function as one-way valves to facilitate injection.

[0012] Preferably, a liquid outlet is fixedly provided on one side of the surface of the second flow channel, and a sealing valve is fixedly provided between the second flow channel and the liquid outlet. PRP liquid can be conveniently discharged through the liquid outlet, and the sealing valve can act as a one-way valve, so that the liquid can only push the sealing film from the second flow channel into the liquid outlet, while the liquid and gas cannot flow back from the liquid outlet into the second flow channel.

[0013] Preferably, the sealing valve is made of an elastic material, and its upper end is fixedly connected to the liquid outlet. This elastic material can be elastic silicone. The fixed connection between the upper end of the sealing valve and the liquid outlet allows it to rotate when subjected to pressure from left to right, thus opening the flow channel. Specifically, it can be as follows: Figure 5 As shown.

[0014] Preferably, a first diaphragm is fixedly disposed in the middle of the partition. The first diaphragm is made of an elastic material. When the balloon is squeezed by the inside of the patient's uterine cavity, the first diaphragm can bulge towards the second flow channel, thereby squeezing the PRP liquid inside the second flow channel. The first diaphragm can be made of elastic medical silicone material.

[0015] Preferably, a second diaphragm is fixedly disposed on the outer surface of the connecting pipe at the upper end of the second flow channel. The second diaphragm is made of elastic material. The function of the second diaphragm is that as more and more PRP liquid is squeezed out of the second flow channel, a vacuum cavity will gradually form in the second flow channel because air cannot enter the interior. At this time, under the action of external air pressure, the second diaphragm can be squeezed, causing the second diaphragm to bulge in the direction of the second flow channel, thereby filling this cavity. If a cavity exists, when the first diaphragm bulges and squeezes the PAP liquid, the liquid will first fill these cavities and cannot be squeezed out from the sealing valve and the outlet, thus losing the function of slow-release PRP liquid.

[0016] Preferably, a baffle is fixedly provided between the second flow channel and the balloon, which can act as a barrier to prevent the second flow channel and the balloon from communicating with each other.

[0017] Compared with the prior art, the beneficial effects of the present invention are:

[0018] 1. This invention innovates the intrauterine PRP injection treatment method by temporarily retaining a portion of the PRP liquid inside the flow channel connected to the balloon. This reduces the amount of PRP liquid injected into the uterine cavity at one time, alleviating the patient's pain. Subsequently, based on the patient's uterine activity, the remaining PRP liquid is automatically and gradually released into the uterine cavity, allowing the patient to receive PRP liquid treatment for a long period of time. This reduces the frequency of hospital visits for the patient. At the same time, the continuously released PRP liquid can continuously treat the patient's uterine cavity, helping the endometrium to repair and proliferate.

[0019] 2. The overall structure of this invention is relatively simple, requiring no other complex power or control structures. It utilizes the squeezing force of the uterus itself during patient activity to pump PRP fluid, pumping a small amount each time to automatically provide sustained-release treatment. Compared to the simple balloon intrauterine stent in traditional technology, it does not increase costs significantly, making it convenient for patients to use without causing financial burden. Attached Figure Description

[0020] Figure 1 This is a schematic diagram of the overall structure of the intrauterine PRP sustained-release device of the present invention.

[0021] Figure 2This is a cross-sectional view of the intrauterine PRP sustained-release device of the present invention.

[0022] Figure 3 In the intrauterine PRP sustained-release device of the present invention Figure 2 Front view,

[0023] Figure 4 This invention relates to an intrauterine PRP sustained-release device. Figure 2 Enlarged view at point A in the middle.

[0024] Figure 5 This invention relates to an intrauterine PRP sustained-release device. Figure 3 A magnified view of point B in the middle.

[0025] In the diagram: 1. Balloon, 2. Connecting tube, 3. Septum, 4. First flow channel, 5. First bend, 6. First catheter seat, 7. First filling valve, 8. Second flow channel, 9. Second bend, 10. Second catheter seat, 11. Second filling valve, 12. Outlet, 13. Sealing valve, 14. First diaphragm, 15. Second diaphragm, 16. Baffle. Detailed Implementation

[0026] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0027] Please see Figure 1-5 This invention provides a technical solution: an intrauterine PRP sustained-release device, including a balloon 1. The lower end of the balloon 1 is provided with a flow guiding mechanism for injecting fluid into the balloon 1. The flow guiding mechanism includes a connecting tube 2, a partition 3, a first flow channel 4, a first bend 5, a first catheter seat 6, and a first filling valve 7. The connecting tube 2 is fixedly provided at the lower end of the balloon 1. The partition 3 is fixedly provided in the middle of the inner side of the connecting tube 2. The first flow channel 4 is provided inside the connecting tube 2 at the lower end of the partition 3. The first bend 5 is fixedly provided on one side of the first flow channel 4. The first filling valve 7 is fixedly provided at the lower end of the first bend 5. The connecting tube 2 is provided with a sustained-release treatment mechanism for intrauterine PRP injection treatment.

[0028] The sustained-release treatment mechanism includes a second flow channel 8, a second bend 9, a second catheter seat 10, and a second filling valve 11. The connecting tube 2 has a second flow channel 8 located at the upper end of the partition 3. A second bend 9 is located on one side of the surface of the second flow channel 8. A second catheter seat 10 is fixedly installed at one end of the second bend 9. A second filling valve 11 is fixedly installed on one side of the surface of the second catheter seat 10. The sustained-release treatment mechanism allows for convenient injection of PRP liquid into the second flow channel 8 using a syringe. The PRP liquid will then fill the second flow channel 8. Continued injection of PRP liquid will cause some of the PRP liquid to be squeezed out from the sealing valve 13 and enter the uterine cavity through the outlet 12 for treatment. The remaining PRP liquid in the second flow channel 8 is retained for slow release later. It should be noted that the first filling valve 7 and the second filling valve 11 in this application are existing technologies and only function as one-way valves to facilitate injection.

[0029] A liquid outlet 12 is fixedly provided on one side of the surface of the second flow channel 8. A sealing valve 13 is fixedly provided between the second flow channel 8 and the liquid outlet 12. PRP liquid can be easily discharged through the liquid outlet 12, while the sealing valve 13 can act as a one-way valve, ensuring that liquid can only push the sealing film from the second flow channel 8 into the liquid outlet 12, while liquid and gas cannot flow back from the liquid outlet 12 into the second flow channel 8.

[0030] The sealing valve 13 is made of an elastic material, and its upper end is fixedly connected to the liquid outlet 12. This elastic material can be elastic silicone. When the upper end of the sealing valve 13 is compressed from left to right, it can rotate to open the flow channel. Specifically, it can be as follows... Figure 5 As shown,

[0031] A first diaphragm 14 is fixedly disposed in the middle of the partition 3. The first diaphragm 14 is made of elastic material. When the balloon 1 is squeezed by the inside of the patient's uterine cavity, the first diaphragm 14 bulges towards the second flow channel 8, thereby squeezing the PRP liquid inside the second flow channel 8. The first diaphragm 14 can be made of elastic medical silicone material.

[0032] A second diaphragm 15 is fixedly disposed on the outer surface of the connecting pipe 2 at the upper end of the second flow channel 8. The second diaphragm 15 is made of elastic material. The function of the second diaphragm 15 is that as more and more PRP liquid is squeezed out from inside the second flow channel 8, a vacuum cavity gradually forms in the second flow channel 8 because air cannot enter inside. At this time, under the action of external air pressure, the second diaphragm 15 can be squeezed, causing the second diaphragm 15 to bulge in the direction of the second flow channel 8, thereby filling this cavity. If a cavity exists, when the first diaphragm 14 bulges and squeezes the PAP liquid, this liquid will first fill these cavities and cannot be squeezed out from the sealing valve 13 and the outlet 12, thus losing the function of slow-release PRP liquid.

[0033] A baffle 16 is fixedly installed between the second flow channel 8 and the balloon 1. The baffle 16 serves as a barrier, preventing the second flow channel 8 and the balloon 1 from communicating with each other.

[0034] Working principle: When using this device, to support the balloon 1, the entire device is inserted into the patient's uterine cavity before the balloon 1 inflates. Then, using a syringe connected to the first filling valve 7, physiological saline is injected. The saline then flows through the first channel 4 into the balloon 1, causing it to inflate and ultimately firmly support the balloon 1 within the uterine cavity, preventing adhesions of the uterine cavity mucosa.

[0035] For PRP injection therapy, a syringe connected to the second filling valve 11 is used to inject PRP into the second flow channel 8. The second flow channel 8 is then filled with PRP. Continued injection causes some PRP to be squeezed out from the sealing valve 13 and enter the uterine cavity through the outlet 12 for treatment. The remaining PRP in the second flow channel 8 is retained for slow release later. This initial squeezing out of PRP minimizes patient pain.

[0036] As balloon 1 expands under the influence of internal saline solution, it supports the uterine cavity, preventing adhesion of the uterine mucosa and aiding in endometrial repair and proliferation. Since its purpose is to prevent adhesion of the uterine mucosa to the inner wall of the uterine cavity, patient movement (lying down, sitting, or walking) causes changes in the internal space of the uterine cavity. These changes inevitably compress balloon 1 against the inner wall of the uterine cavity. This pressure is transmitted through the saline solution inside balloon 1 and the first channel 4, causing deformation of the balloon 1 at the weakest point between the first channel 4 and the second channel 8 (the first septum 14). The first septum 14 protrudes towards the second flow channel 8. Since the second flow channel 8 contains pre-existing RPR fluid, this fluid is compressed, pushing open the sealing valve 13. This allows some RPR fluid to be squeezed out of the outlet 12 and replenish the uterine cavity. This continuously and gradually releases the remaining PRP fluid in the second flow channel 8. The growth factors and other therapeutic drugs within the PRP fluid continuously aid in endometrial repair and proliferation, reducing the frequency of hospital visits by at least half. Subsequently, after uterine contraction ceases to compress the balloon 1, the balloon 1 and the first septum 14 automatically return to their original positions due to their own elasticity.

[0037] As the reserved RPR liquid is squeezed out from the sealing valve 13, the sealing valve 13 acts as a one-way valve, ensuring that the RPR liquid can only be squeezed out from the sealing valve 13, while other liquids and air from the external environment cannot enter the second flow channel 8 (thus preventing the PPR liquid inside the second flow channel 8 from being contaminated). This gradually creates a vacuum gap inside the second flow channel 8, forming a negative pressure. At this time, the external air pressure environment will squeeze the second diaphragm 15, causing the second diaphragm 15 to bulge towards the first diaphragm 14, thereby filling this gap. The purpose is to immediately squeeze the RPR liquid inside the second flow channel 8 each time the first diaphragm 14 bulges towards the second flow channel 8. This allows a small portion of the liquid to be squeezed out from the sealing valve 13 and the outlet 12, thus continuously releasing PRP liquid. (The whole process can be understood as squeezing a bag of yogurt. No matter how much yogurt is squeezed out, the external air pressure compresses the bag, causing it to shrink and leaving no gaps between the bag and the yogurt. Therefore, each squeeze of the yogurt bag will immediately release yogurt.) However, if gaps exist, when the first diaphragm 14 bulges and squeezes the PRP liquid in the second flow channel 8, the liquid will first fill these cavities and cannot be squeezed out from the sealing valve 13 and the outlet 12, thus losing the function of slow-release PRP liquid.

[0038] Furthermore, the overall structure of this device is relatively simple, requiring no other complex power or control structures. It utilizes the squeezing force of the uterine cavity itself during patient movement to pump PRP fluid, pumping a small amount each time to automatically provide sustained-release treatment. Compared to the simple balloon-1 intrauterine stent in traditional technology, it does not increase costs significantly, making it convenient for patients to use without causing financial burden. Moreover, the device has an additional filling valve compared to traditional intrauterine stents, but otherwise, its wearing and use are no different from traditional intrauterine stents.

[0039] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0040] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. An intrauterine PRP sustained-release device, comprising a balloon (1), characterized in that: The lower end of the balloon (1) is provided with a flow guiding mechanism for injecting fluid into the balloon (1). The flow guiding mechanism includes a connecting tube (2), a partition (3), a first flow channel (4), a first bend (5), a first catheter seat (6), and a first filling valve (7). The lower end of the balloon (1) is fixedly provided with a connecting tube (2). The middle inner side of the connecting tube (2) is fixedly provided with a partition (3). The lower end of the partition (3) inside the connecting tube (2) is provided with a first flow channel (4). The first bend (5) is fixedly provided on one side of the first flow channel (4). The lower end of the first bend (5) is fixedly provided with a first filling valve (7). The connecting tube (2) is provided with a slow-release treatment mechanism for intrauterine PRP injection therapy. The release therapy device includes a second flow channel (8), a second bend (9), a second catheter seat (10), and a second filling valve (11). The second flow channel (8) is provided inside the connecting tube (2) at the upper end of the partition (3). The second bend (9) is provided on one side of the surface of the second flow channel (8). The second catheter seat (10) is fixedly provided at one end of the second bend (9). The second filling valve (11) is fixedly provided on one side of the surface of the second catheter seat (10). The first diaphragm (14) is fixedly provided in the middle of the partition (3). The first diaphragm (14) is made of elastic material. The second diaphragm (15) is fixedly provided on the outer surface of the connecting tube (2) at the upper end of the second flow channel (8). The second diaphragm (15) is made of elastic material.

2. The intrauterine PRP sustained-release device according to claim 1, characterized in that: A liquid outlet (12) is fixedly provided on one side of the surface of the second flow channel (8), and a sealing valve (13) is fixedly provided between the second flow channel (8) and the liquid outlet (12).

3. The intrauterine PRP sustained-release device according to claim 2, characterized in that: The sealing valve (13) is made of elastic material, and the upper end of the sealing valve (13) is fixedly connected to the liquid outlet (12).

4. The intrauterine PRP sustained-release device according to claim 1, characterized in that: A baffle (16) is fixedly provided between the second flow channel (8) and the balloon (1).

Images